What's new? Log in Free sign up

XOMA (XOMA)

Company Profile

Company profile

Ticker

XOMA, XOMAP, XOMAO

Exchange

Website

CEO

Mr. Owen P. Hughes Jr.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

XOMA Corp, XOMA CORP /DE/, XOMA LTD /DE/

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

XOMA Technology Ltd. • XOMA (US) LLC • XOMA UK Limited • XRL 1 LLC ...

IRS number

942756657

XOMA stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

HC Wainwright & Co.

Latest filings (excl ownership)

View all

XOMA Royalty Reports Third Quarter 2024 Financial Results

Quarterly report

7 Nov 24

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

MIPLYFFA™ is the first therapy approved for use in patients with NPC, a rare genetic disorder

Amendments to Articles of Incorporation or Bylaws

Notice of effectiveness

Notice of effectiveness

Financial Statements and Exhibits

Submission of Matters to a Vote of Security Holders

Latest ownership filings

View all

THOMAS M. BURNS

JACK L WYSZOMIERSKI

MATTHEW D PERRY

JOSEPH M LIMBER

Natasha Hernday

Heather L Franklin

BIOTECHNOLOGY VALUE FUND L P

Financial summary

Financial statements Chart XOMA financial data

Quarter (USD)	Sep 24	Mar 24	Dec 23	Sep 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	146.82 mm	146.82 mm	146.82 mm	146.82 mm		146.82 mm
Cash burn (monthly)	(no burn)	(no burn)	5.21 mm	4.03 mm		914.42 k
Cash used (since last report)	n/a	n/a	14.60 mm	11.29 mm		2.56 mm
Cash remaining	n/a	n/a	132.22 mm	135.53 mm		144.26 mm
Runway (months of cash)	n/a	n/a	25.4	33.6		157.8

Beta Read what these cash burn values mean

Financial data from XOMA earnings reports.

Institutional ownership, Q2 2024

XOMA institutional ownership history Ownership history

78.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	34	54	-37.0%
Opened positions	11	14	-21.4%
Closed positions	31	9	+244.4%
Increased positions	10	13	-23.1%
Reduced positions	5	15	-66.7%

13F shares	Current	Prev Q	Change
Total value	114.39 bn	78.85 bn	+45.1%
Total shares	9.04 mm	7.61 mm	+18.8%
Total puts	2.20 k	0.00	NEW
Total calls	1.00 k	15.40 k	-93.5%
Total put/call ratio	2.2	–	–

Largest owners	Shares	Value	Change
Biotechnology Value Fund L P	3.63 mm	$75.44 mm	0.0%
BVF	3.63 mm	$86.08 bn	NEW
NVS Novartis	539.13 k	$8.76 mm	0.0%
Stonepine Capital Management	250.13 k	$5.93 bn	NEW
Opaleye Management	250.00 k	$5.92 bn	NEW
MS Morgan Stanley	167.12 k	$3.96 bn	+5.0%
STT State Street	141.10 k	$3.34 bn	+1.6%
Eversept Partners	91.91 k	$2.18 bn	-5.3%
Woodline Partners	72.21 k	$1.71 bn	+0.1%
BK The Bank of New York Mellon Corporation	62.66 k	$1.48 bn	+3.2%

Largest transactions	Shares	Bought/sold	Change
BVF	3.63 mm	+3.63 mm	NEW
FMR	0.00	-1.16 mm	EXIT
BLK BlackRock	0.00	-480.51 k	EXIT
Vanguard	0.00	-405.53 k	EXIT
Stonepine Capital Management	250.13 k	+250.13 k	NEW
Opaleye Management	250.00 k	+250.00 k	NEW
Geode Capital Management	0.00	-170.05 k	EXIT
Acuitas Investments	0.00	-123.20 k	EXIT
TLS Advisors	0.00	-120.37 k	EXIT
HighVista Strategies	0.00	-118.90 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

XOMA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
13 Nov 24	Burns Thomas M.	Common Stock	Sell	Dispose S	No	No	29.94	9,775	292.66 k	14,553
13 Nov 24	Owen Hughes	Common Stock	Sell	Dispose S	No	No	29.95	21,881	655.34 k	34,979
11 Nov 24	Burns Thomas M.	Common Stock	Option exercise	Acquire M	No	No	0	17,773	0.00	24,328
11 Nov 24	Burns Thomas M.	Performance Stock Units Common Stock	Option exercise	Dispose M	No	No	0	17,773	0.00	73,827
11 Nov 24	Owen Hughes	Common Stock	Option exercise	Acquire M	No	No	0	53,360	0.00	56,860
11 Nov 24	Owen Hughes	Performance Stock Units Common Stock	Option exercise	Dispose M	No	No	0	53,360	0.00	221,640
15 May 24	Heather L Franklin	Non-Qualified Share Option Common Shares	Grant	Acquire A	No	No	24.71	9,763	241.24 k	9,763
15 May 24	Wyszomierski Jack L	Common Stock	Grant	Acquire A	No	No	0	6,070	0.00	12,533
15 May 24	Perry Matthew D	Common Stock	Grant	Acquire A	No	No	0	6,070	0.00	17,869

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Buy on XOMA Royalty, Maintains $123 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA Royalty (NASDAQ:XOMA) with a Buy and maintains $123 price target.

HC Wainwright & Co. Maintains Buy on XOMA Royalty, Raises Price Target to $123

HC Wainwright & Co. analyst Joseph Pantginis maintains XOMA Royalty (NASDAQ:XOMA) with a Buy and raises the price target from $117 to $123.

HC Wainwright & Co. Reiterates Buy on XOMA Royalty, Raises Price Target to $123

HC Wainwright & Co. analyst Joseph Pantginis reiterates XOMA Royalty (NASDAQ:XOMA) with a Buy and raises the price target from $117 to $123.

XOMA Royalty Said It Owns An Economic Interest In Seralutinib, A Phase 3 Asset Being Studied In Pulmonary Arterial Hypertension, Through Its Acquisition Of Pulmokine For A $20M In Cash Payment

XOMA Q3 2024 GAAP EPS $(1.59) Misses $(0.44) Estimate, Sales $9.197M Beat $6.493M Estimate

Press releases

From Benzinga Pro

XOMA Royalty Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA's Series A and Series

XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

Seralutinib becomes XOMA Royalty's seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets Seralutinib is being developed and co-commercialized by

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

Zevra's MIPLYFFA™ (arimoclomol) received FDA approval and became the sixth commercial asset in XOMA Royalty's portfolio XOMA Royalty acquired a 50 percent economic interest in TWIST Bioscience's portfolio of

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.